Overall, both agents produce similar placebo‐adjusted symptomatic and functional gains on a background of double‐digit weight loss; semaglutide offers more detailed NT‐proBNP data, while tirzepatide currently shows the clearest HF event‐reduction signal. Here, NPPB is linked to hydrops fetalis.